Open Access

p38 predicts depression and poor outcome in esophageal cancer

  • Authors:
    • Yao Cheng
    • Zhe Qiao
    • Chengxue Dang
    • Bin Zhou
    • Shaomin Li
    • Wei Zhang
    • Jiantao Jiang
    • Yongchun Song
    • Jin Zhang
    • Dongmei Diao
  • View Affiliations

  • Published online on: October 3, 2017     https://doi.org/10.3892/ol.2017.7129
  • Pages:7241-7249
  • Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

0

Abstract

p38 mitogen‑activated protein kinase (MAPK) signaling has been implicated in the cancer development and progression. However, the precise mechanism of this association remains unknown. The aim of the present study was to evaluate the association between p38 and cancer progression, including investigations into the effects on cell proliferation, resistance to thalidomide, indoleamine 2,3‑dioxygenase (IDO) expression and prognosis in patients with esophageal cancer. The present retrospective study included patients with stage I‑III esophageal cancer. A total of 228 patients with esophageal cancer were recruited to analyze the expression of phosphorylated (p)‑p38 and IDO in tumor, and normal tissues through immunohistochemistry. Depression status was measured using the Zung Self‑Rating Depression Scale. P38 cDNA was transfected into esophageal cancer cells to assess tumor cell viability, sensitivity to thalidomide treatment and IDO gene expression. Western blotting and flow cytometry was used to analyze protein expression alterations, and apoptosis in esophageal cancer cells. P‑p38 protein was expressed in 68.9% of cancer tissues, and was significantly associated with depressive symptoms, tumor recurrence and poor survival of patients. In vitro experiments revealed that the expression of p‑p38 induced esophageal cancer Eca‑109 and TE‑1 cell viability, and resistance to thalidomide treatment, as well as in the expression of IDO without the application of lipopolysaccharides. Further follow‑up of patients revealed that depression was also an independent factor for early recurrence and overall survival rate. Altered p38 MAPK expression was associated with poor outcome in patients with esophageal cancer. p38 may be a potential biomarker for the prediction of depressive symptoms and prognosis in patients with esophageal cancer.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Cheng, Y., Qiao, Z., Dang, C., Zhou, B., Li, S., Zhang, W. ... Diao, D. (2017). p38 predicts depression and poor outcome in esophageal cancer. Oncology Letters, 14, 7241-7249. https://doi.org/10.3892/ol.2017.7129
MLA
Cheng, Y., Qiao, Z., Dang, C., Zhou, B., Li, S., Zhang, W., Jiang, J., Song, Y., Zhang, J., Diao, D."p38 predicts depression and poor outcome in esophageal cancer". Oncology Letters 14.6 (2017): 7241-7249.
Chicago
Cheng, Y., Qiao, Z., Dang, C., Zhou, B., Li, S., Zhang, W., Jiang, J., Song, Y., Zhang, J., Diao, D."p38 predicts depression and poor outcome in esophageal cancer". Oncology Letters 14, no. 6 (2017): 7241-7249. https://doi.org/10.3892/ol.2017.7129